Colon Cancer

P=N/A, N=546, Enrolling by invitation, Indiana University | Not yet recruiting --> Enrolling by invitation

In colon cancer, the adverse prognostic signal within T4N0 disease appears to be driven primarily by T4bN0. These findings support reconsideration of current staging paradigms, particularly for T4bN0 colon cancer, and warrant further prospective validation of risk-adapted postoperative strategies.

Notably, elevated miR-501 expression was associated with more than a twofold increased risk of death in stage IV CRC patients from the TCGA-COAD cohort. IL-17 signaling may drive CRC progression and poor clinical outcomes in part through the induction of miR-501-5p, underscoring its potential role in immune-related cancer metastasis and as a prognostic biomarker.

Moreover, MALINC1 knockdown enhanced the sensitivity of these cells to platinum-based drugs. These findings suggest that a prognostic model based on six key disulfidptosis-related lncRNAs holds potential for predicting outcomes in patients with COAD, and that targeting MALINC1 may offer new insights into colorectal cancer chemotherapy.

Our results provided new insights into the mechanisms of intestinal cancer progresses by paracrine IR-PD-L1 signaling, which is aided by the deregulation of oxidative stress and macrophage communication brought on by smoking carcinogen-induced the metabolic syndrome.

P=N/A, N=4186, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Apr 2026

P=N/A, N=90, Completed, Universidad de Granada | Active, not recruiting --> Completed

In conclusion, SalB modulates CRC drug resistance through multiple targets and pathways. SalB potentially reverses oxaliplatin resistance in CRC cells by regulating the ROS-mediated apoptotic signalling pathway.

Puerarin halted the malignant progression of CRC by reprogramming tumor lipid metabolism. Puerarin thus hold promise as a clinically deployable lipid-centric agent that could synergistically potentiate conventional anticancer drugs.

Furthermore, bacterial elimination and tumor cell damage were accompanied by modulation of the tumor immune microenvironment, including enhanced dendritic cell maturation and increased cytotoxic CD8+ T-cell infiltration. Collectively, this AiDCs strategy provides a promising approach for the treatment of intratumoral bacteria-associated, drug-resistant malignancies.

Peroxisomes act as pivotal regulators of digestive cancer progression by modulating signaling pathways, the TIME, therapeutic resistance, and lipid metabolism. Targeting peroxisomal function, particularly in high-risk subgroups of HCC and CRC, warrants further exploration as a promising therapeutic strategy.

NAT10 promotes colon cancer progression in an enzymatic activity‑dependent manner by enhancing predicted ac4C modification of Notch2 mRNA to stabilize its expression. This study reveals a novel NAT10/ac4C/Notch2 regulatory axis and provides potential therapeutic targets for colon cancer.